---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061836"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:09:35.523196+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.73
calibrated_materiality_score: 0.73
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned

## Summary
- NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.
- Earned $45 million milestone from Kyowa Kirin for NDA submission; pro forma cash $703.2M.
- Q1 collaboration revenue $14.1M (vs $0 in Q1 2024); R&D expenses $56.0M, up 54% YoY.
- Cash, equivalents and short-term investments $658.2M at March 31, 2025; runway into 2027.
- First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST; data at ASCO and EHA upcoming.

## SEC filing metadata
- accession: 0000950170-25-061836
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.73
- calibrated_materiality_score: 0.73
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/0000950170-25-061836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061836
- JSON: https://secwatch.observer/filing/0000950170-25-061836.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.